Use of prostaglandin E1 for prevention of liver veno‐occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation

British Journal of Haematology - Tập 74 Số 3 - Trang 277-281 - 1990
Éliane Gluckman1, Isabelle Jolivet2, Marie‐Lorraine Scrobohaci3, A Devergié4, R Traineau4, H Bourdeau-Espérou4, P Lehn4, Paul A. Faure4, Ludovic Drouet3
1Bone Marrow Transplant Unit, Hopital Saint-Louis, Paris, France.
2Pharmacy, Hopital Saint‐Louis, Paris, France
3Coagulation Department, Paris, France
4Bone Marrow Transplant Unit, Paris, France

Tóm tắt

SummaryProstaglandin E1 (PGE1) was used to prevent veno‐occlusive disease (VOD) of the liver after allogeneic bone marrow transplantation (BMT) for leukaemia. It was given in continuous i.v. infusion from day – 8 to day 30 after BMT at a dose of 0.3 μg/kg/h. The patients were studied according to the risk factors for VOD: diagnosis, intensification of the conditioning and previous liver abnormalities. The diagnosis of VOD was made on at least two of the following factors: weight gain, hepatomegaly, jaundice, ascitis, pain of the right upper quadrant, increased platelet consumption. 109 patients were studied, 50 were treated by PGE1 and 59 did not receive it. The actuarial incidence of VOD was 12.2% in the PGE1 group and 25.5% in the non PGE1 group (P=0.05). In acute leukaemia, the incidence was 39.1% in the non‐treated group and 12.8% in the PGE1 treated group (P=0.02). Patients with previous hepatitis had an incidence of 62.5% in the non treated group and 15.5% in the treated group (P=0.05). A positive cytomegalovirus (CMV) serology seemed to increase the risk of VOD: the incidence of VOD was 31.4% in non‐treated patients and 22% in PGE1 treated patients. The multivariate analysis of the risk factors for VOD shows that unfavourable factors were: recipient positive CMV serology (P=0.06), hepatic disease prior to transplant (P=0.02) and the absence of PGE1 treatment (P=0.02). This study suggests that prophylactic PGE1 treatment may decrease the incidence of VOD in patients treated for leukaemia by allogeneic bone marrow transplantation.

Từ khóa


Tài liệu tham khảo

10.1042/bj1200709

Beschorner W.E., 1980, Pathology of the liver with bone marrow transplantation. Effects of busulfan, carmustine, acute graft versus host disease and cytomegalovirus infection, American Journal of Pathology, 99, 369

Brugieres L., 1988, Venoocclusive disease of the liver following high‐dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome, Bone Marrow Transplantation, 3, 53

Cahn J.Y., 1985, Maladie veino‐occlusive du foie et autogreffe de moelle osseuse. Rôle préventif de l'héparine, Nouvelle Revue Française d'Hématologie, 27, 27

Clifford P.C., 1983, Prostaglandin E1 infusion for small vessel arterial ischaemia, Journal of Cardiovascular Surgery, 24, 503

Crutchley D.J., 1982, Stimulation of fibrinolytic activity in human skin fibroblasts by prostaglandins E1 E2 and I2, Journal of Pharmacology and Experimental Therapeutics, 222, 544

Devergie A., 1986, Changes in endothelial and coagulation para meters after allogeneic bone marrow transplant as a mean of prediction of veno‐occlusive disease, Experimental Hematology, 14, 430

Dulley F.L., 1987, Venocclusive disease of the liver after chemo radiotherapy and autologous bone marrow transplantation, Transplantation, 43, 870, 10.1097/00007890-198706000-00020

10.1016/S0140-6736(75)91432-4

10.1016/0360-3016(88)90009-0

Gluckman E., 1988, Use of Cyclosporine for prevention of graft versus host disease after allogeneic bone marrow transplantation, Transplantation Proceedings, 20, 461

10.1056/NEJM197609022951004

10.1002/hep.1840040121

10.1097/00007890-198506000-00005

10.1016/0016-5085(86)90949-2

10.1016/0016-5085(87)90985-1

10.1056/NEJM198809153191106

Pardy B.J., 1980, Preliminary experience with prostaglandins E1 and I2 in peripheral vascular disease, Surgery, 88, 826

10.1182/blood.V67.6.1773.1773

Shulman H.M., 1987, Induction of hepatic veno‐occlusive disease in dogs, American Journal of Pathology, 126, 114

Shulman H.M., 1984, The Pathology of Bone Marrow Transplantation, 104

10.1016/0016-5085(80)90911-7

10.1002/hep.1840080305

10.1111/j.1365-2362.1988.tb01266.x

10.1002/hep.1840090317

Vaughan D.E., 1989, PGE1 accelerates thrombolysis by tissue plasminogen activator, Blood, 73, 1213, 10.1182/blood.V73.5.1213.1213

Thông tin
Thông tin xuất bản

British Journal of Haematology

Tập 74 Số 3

277-281

Thông tin tác giả